How long should aspirin and Plavix (clopidogrel) be continued after Watchman implantation?

Antiplatelet Therapy Duration After Watchman Implantation

Based on the most recent high-quality evidence, aspirin and clopidogrel should be continued for 6 months after Watchman implantation, followed by aspirin indefinitely. 1

Standard Post-Watchman Antithrombotic Regimen

The 2024 ESC guidelines provide the most current recommendations for post-Watchman anticoagulation management 1:

Initial Phase (First 45 Days)

• Warfarin (INR 2.0-2.5) plus aspirin 81 mg daily for 45 days 1
• Alternative: Full-dose DOAC plus aspirin for 45 days (increasingly used in real-world practice) 1
• At 45 days: Perform transesophageal echocardiography to assess for device-related thrombus and peri-device leak 1

Intermediate Phase (45 Days to 6 Months)

• Dual antiplatelet therapy (aspirin 81 mg plus clopidogrel 75 mg daily) for 6 months total from implantation 1
• This assumes no major peri-device leaks (>5mm) and no device-related thrombus on 45-day imaging 2

Long-Term Maintenance (After 6 Months)

• Aspirin 81 mg daily indefinitely 1, 2

Alternative Strategies for High Bleeding Risk Patients

For patients with absolute contraindications to oral anticoagulation (the primary indication for Watchman), modified regimens have been studied 3, 4:

Antiplatelet-Only Strategy

• Dual antiplatelet therapy (aspirin plus clopidogrel) for 6 months, followed by aspirin indefinitely 2, 3
• This approach showed similar thromboembolic outcomes compared to warfarin-based regimens, though device-related thrombus was slightly more common (3.1% vs 1.4%) 3
• No difference in major bleeding or stroke rates at 6 months between antiplatelet-only and warfarin-based strategies 3

Shortened Duration Regimens

• Some centers have successfully used 6 weeks of anticoagulation followed by 6 weeks of dual antiplatelet therapy, then aspirin alone 5
• This approach showed no ischemic strokes between 45 days and 4 months when first imaging was delayed to 4 months 5

Critical Timing Considerations

The vulnerable period for device-related thrombus is after discontinuing anticoagulation, not before. 5 This explains why:

• Device-related thrombus is most commonly detected at 4-12 months post-implantation, not at 45 days 5
• The 45-day TEE is performed while patients are still anticoagulated, making it unlikely to detect thrombus 5
• Most thromboembolic events occur after transitioning to antiplatelet therapy alone 5

Imaging Surveillance Schedule

Standard protocol 1, 2:

• TEE at 45 days to assess device position and rule out early thrombus
• TEE at 12 months to detect late device-related thrombus
• Some centers advocate for imaging at 4 months instead of 45 days, as this captures the true vulnerable period after anticoagulation discontinuation 5

Common Pitfalls to Avoid

1. Do not discontinue anticoagulation at 45 days if significant peri-device leak (>5mm) is present - continue anticoagulation and repeat imaging 1

2. Do not use prasugrel or ticagrelor instead of clopidogrel - only clopidogrel has been studied in Watchman trials 3

3. Do not use high-dose aspirin (>100 mg) - low-dose aspirin (75-100 mg) is preferred to minimize bleeding risk 1

4. Do not skip the 45-day imaging - this is essential to rule out early complications before transitioning therapy 1

5. Device-related thrombus can occur up to 1 year post-implantation - maintain vigilance for thromboembolic symptoms throughout the first year 5

DOAC Use After Watchman

While not part of original trial protocols, DOACs are increasingly used as alternatives to warfarin in the initial 45-day period 1, 6:

• Rivaroxaban, dabigatran, and apixaban have been used successfully 1, 6
• No increase in device-related thrombus or bleeding compared to warfarin 6
• Preferred over warfarin by recent European guidelines when combination antiplatelet therapy is required 1